GlassScriptPhysician profile
Amy Kelly
NPI 1578173555
$5,836.64
in general payments reported to CMS, 2019-2025
29 companies · $2,057 in 2025
The $2,057 reported for 2025 was more than what 94% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $706 · 2022: $368 · 2023: $1,313 · 2024: $1,392 · 2025: $2,057.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,628 · Education: $135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,627.61 |
| Education | $134.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,587.51 | 2021-2025 | Fasenra, Tezspire, Airsupra |
| Genzyme Corporation | $842.95 | 2021-2025 | |
| Glaxosmithkline, LLC. | $779.83 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Regeneron Healthcare Solutions, INC. | $727.73 | 2021-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $310.14 | 2021-2024 | Ofev |
| Insmed, INC. | $292.17 | 2021-2025 | Arikayce, Brinsupri |
| Philips North America LLC | $143.82 | 2021-2025 | Vest Therapy Und |
| Pulmonx Corporation | $142.78 | 2024 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Amgen INC. | $135.48 | 2023-2025 | Tezspire, Tavneos |
| United Therapeutics Corporation | $130.86 | 2021-2025 | Tyvaso |
| Takeda Pharmaceuticals U.S.A., INC. | $130.71 | 2021-2025 | Glassia |
| Sanofi-Aventis U.S. LLC | $99.95 | 2023 | |
| Baxter Healthcare | $55.67 | 2023-2025 | Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care |
| Mylan Specialty L.P. | $50.52 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $50.39 | 2021-2023 | Opsumit |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $48.58 | 2025 | Rystiggo |
| Abbvie INC. | $48.03 | 2023-2024 | |
| Gilead Sciences, INC. | $40.72 | 2021 | |
| Genentech USA, INC. | $34.37 | 2023-2025 | Xolair, Ocrevus Zunovo |
| Aimmune Therapeutics, INC. | $24.63 | 2025 | Vowst |
| Viatris Specialty LLC | $23.09 | 2025 | Yupelri |
| Verona Pharma, INC. | $22.26 | 2025 | Ohtuvayre |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $20.75 | 2022 | |
| Argenx US, INC. | $20.59 | 2025 | Vyvgart Hytrulo |
| Phadia US INC. | $15.52 | 2021 | |
| Livanova USA, INC. | $15.26 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Janssen Biotech, INC. | $15.17 | 2023 | Stelara |
| Phathom Pharmaceuticals, INC. | $14.20 | 2023 | Voquezna |
| Braintree Laboratories, INC. | $12.96 | 2023 | Suflave, Sutab |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Kelly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.